HealthlineNew Breast Density Treatment May Have Fewer Side Effects, Lower Cancer Risk

⚠️ Small Study / Early Comparative Evidence

The randomized, double-blind, placebo-controlled KARISMA Endoxifen phase II trial evaluated whether low-dose (Z)-endoxifen could reduce mammographic breast density, a recognized breast cancer risk marker. Both 1 mg and 2 mg daily doses produced substantial density reductions, with the lower dose demonstrating the most favorable tolerability profile.

Clinical Considerations

• Women receiving 1 mg endoxifen experienced a 19.3% reduction in mammographic breast density versus placebo.
• The 2 mg dose reduced density by 26.5%, though vasomotor symptoms increased compared with placebo.
• Density reduction appeared to plateau at plasma concentrations of approximately 3 to 4 ng/mL.
• Investigators reported no clinically significant changes in laboratory values, hematology parameters, or vital signs.

Practice Applications

• Recognize mammographic breast density as an established breast cancer risk marker.
• Interpret endoxifen findings as surrogate-endpoint evidence rather than cancer-prevention outcomes.
• Monitor future trials evaluating breast cancer incidence and long-term safety.
• Consider adherence implications when lower-dose prevention approaches are studied.